A detailed history of High Tower Advisors, LLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 36,612 shares of IBRX stock, worth $164,387. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,612
Holding current value
$164,387
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.32 - $6.7 $121,551 - $245,300
36,612 New
36,612 $135,000
Q1 2024

May 06, 2024

BUY
$3.23 - $6.17 $33,275 - $63,563
10,302 New
10,302 $55,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.8B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.